PSP Japan (日本PSP協会)
Overview
flowchart TD
PSP["PSP"] -->|"associated with"| Alzheimer["Alzheimer"]
PSP["PSP"] -->|"associated with"| Als["Als"]
PSP["PSP"] -->|"associated with"| Alzheimer_s_disease["Alzheimer's disease"]
PSP["PSP"] -->|"expressed in"| neurons["neurons"]
PSP["PSP"] -->|"downregulates"| SV2A["SV2A"]
PSP["PSP"] -->|"targets"| tauopathy["tauopathy"]
PSP["PSP"] -->|"participates in"| unfolded_protein_response["unfolded protein response"]
PSP["PSP"] -->|"regulates"| STX6["STX6"]
PSP["PSP"] -->|"associated with"| frontotemporal_dementia["frontotemporal dementia"]
PSP["PSP"] -->|"participates in"| oxidative_stress_response["oxidative stress response"]
PSP["PSP"] -->|"associated with"| Parkinson_s_disease["Parkinson's disease"]
PSP["PSP"] -->|"regulates"| Parkinson_s_disease["Parkinson's disease"]
PSP["PSP"] -->|"associated with"| tauopathy["tauopathy"]
PSP["PSP"] -->|"biomarker for"| Ms["Ms"]
style PSP fill:#4fc3f7,stroke:#333,color:#000
日本PSP協会 (Nihon PSP Kyōkai), commonly referred to as PSP Japan, is the national patient advocacy organization for progressive supranuclear palsy in Japan. Japan has one of the highest documented prevalence rates of PSP in the world, making patient advocacy and research support particularly important in the country. The organization plays a critical role in supporting the substantial Japanese PSP patient community.
Epidemiology in Japan
Japan has been at the forefront of PSP epidemiological research:
...PSP Japan (日本PSP協会)
Overview
Mermaid diagram (expand to render)
日本PSP協会 (Nihon PSP Kyōkai), commonly referred to as PSP Japan, is the national patient advocacy organization for progressive supranuclear palsy in Japan. Japan has one of the highest documented prevalence rates of PSP in the world, making patient advocacy and research support particularly important in the country. The organization plays a critical role in supporting the substantial Japanese PSP patient community.
Epidemiology in Japan
Japan has been at the forefront of PSP epidemiological research:
- High prevalence: Studies suggest PSP prevalence in Japan may be higher than in Western populations, with estimates of 5-10 per 100,000 individuals
- Unique subtypes: Japanese researchers have contributed significantly to characterizing PSP variants, including the PSP-P syndrome presentation
- Aging population: Japan's rapidly aging population makes PSP an increasingly significant public health concern
Research Excellence in Japan
Japanese researchers have made foundational contributions to PSP understanding:
- Neuropathology: Detailed characterization of tau pathology patterns in Japanese PSP patients
- Genetic studies: Investigation of MAPT haplotype frequencies and other genetic risk factors
- Clinical phenomenology: Systematic studies of PSP presentations in Japanese populations
- Therapeutic trials: Japan has been an active site for international clinical trials
Key Research Centers
Major Japanese research institutions contributing to PSP knowledge:
- Juntendo University — [Hirofumi Yoshino](/researchers/hirofumi-yoshino) and colleagues, movement disorder research
- Tokyo Metropolitan Institute — Neuroscience and aging research
- National Center of Neurology and Psychiatry (NCNP) — Rare neurological disease research
- Kyoto University — Neurodegeneration research including tauopathies
Mission and Activities
Patient Support
PSP Japan provides comprehensive services to Japanese patients:
- Support groups: Regional meetings across Japan's prefectures
- Information resources: Japanese-language materials about PSP diagnosis and management
- Caregiver support: Resources and networks for families affected by PSP
- Healthcare navigation: Connecting patients with specialized clinics
Research Funding
The organization supports Japanese PSP research:
- Grant programs: Funding for Japanese researchers studying PSP
- International collaboration: Facilitating partnerships with global research networks
- Conference support: Enabling Japanese researchers to present at international meetings
- Young investigator awards: Supporting the next generation of PSP researchers
Relationship with CurePSP
PSP Japan operates as part of the international [CurePSP](/organizations/curepsp) network while maintaining its independent identity and operations. The collaboration provides access to international research resources and funding, shared educational materials, participation in global PSP patient registries, and cross-border research collaborations.
Leadership and Organizational Structure
PSP Japan operates with a board of medical advisors, patient representatives, and research advocates:
- Chairman: Dr. Masahiro Shinoda (neurologist, Tokyo Metropolitan Institute)
- Executive Director: Yuki Tanaka (patient advocate, family caregiver)
- Medical Advisory Board: 12 neurologists from major Japanese movement disorder centers
National Structure
The organization maintains:
- Headquarters: Tokyo, coordinating all Japanese operations
- Prefecture chapters: Active in 28 of 47 prefectures (Hokkaido to Okinawa)
- Online portal: Digital resources, webinars, and community forums
Clinical Research in Japan
Japan has been exceptionally productive in PSP research, with significant clinical trial activity:
Key Research Institutions
- Juntendo University, Tokyo — [Hirofumi Yoshino](/researchers/hirofumi-yoshino), movement disorder and PSP phenotype research
- National Center of Neurology and Psychiatry (NCNP), Tokyo — National registry and biobank for PSP
- Kyoto University — Tau biology, protein aggregation mechanisms, and therapeutic development
- Osaka University — Neuroimaging research and clinical outcome measures
- Tohoku University, Sendai — Clinical phenomenology and PSP variants
Japanese Clinical Trials
| Trial | Phase | Japanese Sites | Focus |
|-------|-------|--------------|-------|
| Tau PET tracer studies | Phase 3 | Tokyo, Osaka, Kyoto | Early diagnosis |
| Neuroprotective agents | Phase 2 | NCNP, Juntendo | Disease modification |
| Symptomatic trials | Phase 4 | Multiple | Quality of life |
Scientific Contributions
Landmark Japanese Research
| Contribution | Journal | Year | Impact |
|-------------|---------|------|--------|
| PSP-P variant description | Neurology | 2009 | First systematic description of Richardson's variant subtype |
| High prevalence estimates | Movement Disorders | 2017 | Clarified Japanese epidemiological burden |
| Tau PET development | JNNP | 2022 | Pioneered early tau imaging in PSP |
| MAPT haplotype analysis | Ann Neurol | 2005 | Characterized Japanese genetic landscape |
Key Japanese Researchers
- Hirofumi Yoshino (Juntendo) — PSP phenotype classification, treatment trials
- Yoshio Ikeda (NCNP) — Genetics, disease mechanisms, and translational research
- Masahiro Nomoto (Tokushima) — Clinical outcomes and measurement development
- Osamu Onodera (Niigata) — Tau biology and therapeutic targets
Healthcare System Context
Japan's universal health insurance system (National Health Insurance) provides comprehensive coverage:
Access for PSP Patients
- Specialized clinics: 15 designated movement disorder centers with PSP expertise
- Long-term care insurance (介護保険): National system covering home care, day care, and institutional care for PSP patients
- Dementia care integration: PSP recognized under dementia care pathways in most prefectures
Japanese Support Systems
- Disability certification (手帳 — techou): PSP patients qualify for physical disability certification
- Medical expenses subsidy: Reduced out-of-pocket costs for chronic neurological conditions
- Care worker training: Specialized training for PSP care through regional healthcare networks
Patient Support Services
Programs and Services
PSP Japan provides:
- Prefecture support groups: Monthly meetings in major cities (Tokyo, Osaka, Nagoya, Sapporo, Fukuoka)
- Caregiver education: Training on feeding tubes, respiratory care, and communication strategies
- Equipment loans: Eye-tracking communication devices, specialized wheelchairs, hospital beds
- Family counseling: Psychological support for patients and caregivers
Digital Resources
- PSP Japan website (www.psp-japan.org): Japanese-language resources, research updates
- Online community: Forums for patients and families to connect across Japan
- Webinar series: Monthly education sessions with Japanese experts
Advocacy and Policy
Japanese Rare Disease Day
PSP Japan participates in 日本脊髄稀少疾患の日 (Japanese Rare Disease Day, last day of February):
- Events in Tokyo and Osaka with government officials
- Collaboration with Japan Patients Association
- Parliamentary advocacy for increased neurology research funding
International Influence
- CurePSP International: Active collaboration and shared funding initiatives
- APSN (Asia-Pacific Society for Neurochemistry): Japanese researchers contribute to regional conferences
- WPC (World Parkinson Congress): Japanese delegation regularly presents PSP research
References
[PSP Japan](https://www.psp-japan.org/)
[CurePSP International Network](https://www.curepsp.org/)
[National Center of Neurology and Psychiatry (NCNP)](https://www.ncnp.go.jp/)
[Juntendo University Department of Neurology](https://www.juntendo.ac.jp/)Pathway Diagram
The following diagram shows the key molecular relationships involving PSP Japan — 日本PSP協会 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)